These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. First-in-human uPAR PET: Imaging of Cancer Aggressiveness. Persson M; Skovgaard D; Brandt-Larsen M; Christensen C; Madsen J; Nielsen CH; Thurison T; Klausen TL; Holm S; Loft A; Berthelsen AK; Ploug M; Pappot H; Brasso K; Kroman N; Højgaard L; Kjaer A Theranostics; 2015; 5(12):1303-16. PubMed ID: 26516369 [TBL] [Abstract][Full Text] [Related]
3. Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma. Persson M; Nedergaard MK; Brandt-Larsen M; Skovgaard D; Jørgensen JT; Michaelsen SR; Madsen J; Lassen U; Poulsen HS; Kjaer A J Nucl Med; 2016 Feb; 57(2):272-8. PubMed ID: 26429955 [TBL] [Abstract][Full Text] [Related]
4. First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts. Persson M; Liu H; Madsen J; Cheng Z; Kjaer A Nucl Med Biol; 2013 Jul; 40(5):618-24. PubMed ID: 23602763 [TBL] [Abstract][Full Text] [Related]
5. Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging. Persson M; El Ali HH; Binderup T; Pfeifer A; Madsen J; Rasmussen P; Kjaer A Nucl Med Biol; 2014 Mar; 41(3):290-5. PubMed ID: 24533988 [TBL] [Abstract][Full Text] [Related]
6. [(68)Ga]NODAGA-RGD - Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis. Haubner R; Finkenstedt A; Stegmayr A; Rangger C; Decristoforo C; Zoller H; Virgolini IJ Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2005-13. PubMed ID: 27164900 [TBL] [Abstract][Full Text] [Related]
8. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers. Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391 [TBL] [Abstract][Full Text] [Related]
9. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer. Pfob CH; Ziegler S; Graner FP; Köhner M; Schachoff S; Blechert B; Wester HJ; Scheidhauer K; Schwaiger M; Maurer T; Eiber M Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1962-70. PubMed ID: 27207281 [TBL] [Abstract][Full Text] [Related]
10. Whole-body distribution and radiation dosimetry of (68)Ga-NOTA-RGD, a positron emission tomography agent for angiogenesis imaging. Kim JH; Lee JS; Kang KW; Lee HY; Han SW; Kim TY; Lee YS; Jeong JM; Lee DS Cancer Biother Radiopharm; 2012 Feb; 27(1):65-71. PubMed ID: 22149685 [TBL] [Abstract][Full Text] [Related]
11. Prospective Phase II Trial of Prognostication by Carlsen EA; Loft M; Loft A; Berthelsen AK; Langer SW; Knigge U; Kjaer A J Nucl Med; 2022 Sep; 63(9):1371-1377. PubMed ID: 35058319 [TBL] [Abstract][Full Text] [Related]
12. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts. Persson M; Rasmussen P; Madsen J; Ploug M; Kjaer A Nucl Med Biol; 2012 Oct; 39(7):962-9. PubMed ID: 22739362 [TBL] [Abstract][Full Text] [Related]
13. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion. Persson M; Madsen J; Østergaard S; Jensen MM; Jørgensen JT; Juhl K; Lehmann C; Ploug M; Kjaer A J Nucl Med; 2012 Jan; 53(1):138-45. PubMed ID: 22213823 [TBL] [Abstract][Full Text] [Related]
14. Urokinase Plasminogen Activator Receptor-PET with Skovgaard D; Persson M; Kjaer A PET Clin; 2017 Jul; 12(3):311-319. PubMed ID: 28576169 [TBL] [Abstract][Full Text] [Related]
15. Improved positron emission tomography imaging of glioblastoma cancer using novel Loft MD; Sun Y; Liu C; Christensen C; Huang D; Kjaer A; Cheng Z Amino Acids; 2017 Jun; 49(6):1089-1100. PubMed ID: 28316028 [TBL] [Abstract][Full Text] [Related]
16. Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD. Zhang J; Niu G; Lang L; Li F; Fan X; Yan X; Yao S; Yan W; Huo L; Chen L; Li Z; Zhu Z; Chen X J Nucl Med; 2017 Feb; 58(2):228-234. PubMed ID: 27493267 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with Risør LM; Clausen MM; Ujmajuridze Z; Farhadi M; Andersen KF; Loft A; Friborg J; Kjaer A J Nucl Med; 2022 Aug; 63(8):1169-1176. PubMed ID: 34857658 [TBL] [Abstract][Full Text] [Related]
18. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer. Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015 [TBL] [Abstract][Full Text] [Related]
19. A novel urokinase plasminogen activator receptor-targeted peptide-based probe for in-vivo molecular imaging of glioblastoma. Han Y; Tu L; Zhang Y; Xu L; Sun Z Nucl Med Commun; 2023 Feb; 44(2):142-149. PubMed ID: 36630218 [TBL] [Abstract][Full Text] [Related]
20. Safety, Biodistribution, and Radiation Dosimetry of Nicolas GP; Beykan S; Bouterfa H; Kaufmann J; Bauman A; Lassmann M; Reubi JC; Rivier JEF; Maecke HR; Fani M; Wild D J Nucl Med; 2018 Jun; 59(6):909-914. PubMed ID: 29025985 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]